SKYE
Skye BioscienceFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade F from latest DB weights. Momentum 6.1 / Value 58.6
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
6
Value
59
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.25
Why
Momentum6 · Δ7d -
Value59 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
6
52% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
48% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 6.1 / Value 58.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$26.71M
Beta
2.86
Shares Out
32.06M
P/E (TTM) · Derived
-1.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.80
Rev YoY
-
EPS YoY
-220.2%
Gross Margin
-
Op Margin
-
Net Debt
-$70.41M
Current Ratio
4.77
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology